LOTTE HOLDINGS has placed its bet on treatments that could make a real difference for conditions affecting millions of people worldwide. The Japanese conglomerate’s new healthcare venture capital arm has invested in Elixiron Immunotherapeutics, a biotech company developing potential therapies for vitiligo and Alzheimer’s disease. For professionals juggling demanding careers while managing long-term health concerns, this investment targets diseases where effective treatment options remain frustratingly limited.
Japanese Investment in Medical Development
LOTTE HOLDINGS established its Healthcare and Biopharmaceutical Corporate Venture Capital arm in August last year, marking the company’s push into the healthcare sector. This new investment vehicle represents a significant change from the group’s traditional focus on confectionery and food products. Their first investment went to Nuvig Therapeutics in December last year , followed by the recent Elixiron funding.
No ads. No tracking.
We don’t run ads or share your data. If you value independent content and real privacy, support us by sharing.
Read More
The move brings Japanese capital to bear on serious unmet medical needs, with LOTTE’s venture arm targeting companies developing biopharmaceuticals and next-generation therapies across all development stages globally. President and CEO Genichi Tamatsuka’s company aims to ‘address significant unmet medical needs and contribute to improving people’s well-being’ through these healthcare investments.
Vitiligo: A Widespread Condition with Limited Options
Vitiligo affects approximately 70 million people worldwide, representing 0.5% to 2% of the global population. This chronic autoimmune condition destroys melanocytes, the cells responsible for skin pigmentation, creating distinctive white patches that can significantly impact quality of life. The psychological burden proves particularly challenging, with patients frequently experiencing anxiety, depression and social stigma , especially among individuals with darker skin tones.
Until 2022, no systemic treatment had received FDA approval for vitiligo. The situation changed modestly when Opzelura (ruxolitinib) cream gained approval as the first topical treatment for nonsegmental vitiligo in patients aged 12 and older. However, systemic therapies that could address the condition from within the body remain absent from treatment options.
Elixiron’s Indemakitug represents a different approach entirely. This first-in-class anti-IFN-γ monoclonal antibody targets interferon-gamma, a protein that plays a key role in immune system signalling. Anti-interferon-gamma antibodies work by neutralising IFN-γ activity , which can drive inflammatory responses in autoimmune conditions. The drug has shown ‘favourable pharmacokinetics and safety profile in Phase I trials’, with a Phase II proof-of-concept trial scheduled for late this year.
Targeting Alzheimer’s Through Brain Inflammation
Japan faces particularly acute challenges with Alzheimer’s disease, recording one of the world’s highest prevalence rates at approximately 2,637 cases per 100,000 people. The country’s rapidly ageing population means that an estimated 4.6 million Japanese lived with dementia in 2015 , a figure projected to reach seven million by 2025, representing one in five elderly people. Alzheimer’s accounts for roughly 60% to 80% of dementia cases.
Current Alzheimer’s treatments provide modest symptom relief but fail to address the underlying disease progression. Elixiron’s second lead programme, Enrupatinib, takes aim at neuroinflammation, which many researchers now recognise as a key driver of cognitive decline. This brain-penetrant CSF-1R inhibitor targets specific immune cells called microglia within the brain.
CSF-1R inhibitors reduce microglial proliferation and modulate inflammatory signalling pathways , potentially slowing the neuroinflammatory processes that contribute to Alzheimer’s progression. Enrupatinib is currently in Phase II clinical trials, with top-line results expected in late 2026.
The Reality of Drug Development Challenges
Moving from laboratory concept to proven therapy remains extraordinarily difficult. Only about 28% to 50% of drugs successfully progress from Phase II to Phase III studies , with Phase II representing the critical hurdle where many treatments fail due to insufficient efficacy or safety concerns. Overall success rates from Phase I to market approval hover around 9.6%.
Many diseases lack systemic therapies because of these fundamental challenges. Only 5% to 15% of rare diseases have approved treatments, leaving significant unmet medical needs. Even for more common conditions like vitiligo, developing effective systemic therapies requires overcoming complex biological mechanisms, lengthy clinical trial processes and substantial investment risks.
The geographic dispersion of patients, small study populations for rare conditions and the high costs of clinical development – often exceeding 10 years and hundreds of millions of dollars – create substantial barriers. These factors explain why conditions affecting millions of people worldwide can still lack adequate treatment options.
Evidence-Based Approaches Matter
For working professionals concerned about long-term health, the distinction between evidence-based medicine and marketing promises becomes crucial. Both Indemakitug and Enrupatinib target clinically validated pathways – interferon-gamma in autoimmune conditions and CSF-1R in neuroinflammation – based on substantial scientific understanding rather than speculative mechanisms.
The practical importance of targeted therapies extends beyond individual patient outcomes. Effective treatments for chronic conditions like vitiligo and Alzheimer’s disease can reduce the broader healthcare burden, allowing people to maintain productive lives while managing their conditions. For those in high-pressure work environments, having reliable treatment options provides crucial peace of mind when facing potential health challenges.
LOTTE HOLDINGS’ investment reflects this focus on addressing genuine medical needs rather than pursuing fashionable trends. The company’s commitment to ‘improving people’s well-being and creating a healthier society through advanced medical solutions’ aligns with the practical concerns of individuals seeking treatments that actually work.
These Japanese-backed therapies remain unproven and unavailable to patients. However, the funding enables the necessary clinical trials that will determine whether Indemakitug and Enrupatinib can deliver meaningful benefits for people living with vitiligo and Alzheimer’s disease. The results from upcoming Phase II studies will provide clearer answers about whether these approaches can bridge the gap between scientific promise and clinical reality.
